Latest Derivatives News

De.mem Limited has acquired Core Chemicals Pty Ltd for $2.68 million, nearly doubling its EBITDA and positioning itself to capitalise on a surging gold sector. The deal combines strong recurring revenues with significant synergy potential.

Alkane Resources reports its inaugural JORC-compliant Mineral Resources and Ore Reserves for the Costerfield Property, highlighting a robust resource base and a mine life extended to 2030. The recent True Blue Deposit discovery further bolsters the project’s potential.

BlackRock Investment Management has released the estimated distribution components for its iShares S&P/ASX Dividend Opportunities ESG Screened ETF for the period ending 9 October 2025, highlighting key income sources and tax considerations.

ABx Group reports outstanding impurity removal results from bulk sample tests at its Deep Leads rare earth project, retaining over 98% of critical rare earths and advancing towards a mixed rare earth carbonate product sample in late 2025.

PYC Therapeutics has reported encouraging pre-clinical results for its RNA therapy candidate PYC-002 targeting Phelan-McDermid Syndrome, supporting plans to enter human trials in 2026. The data demonstrate safety, brain distribution, and gene expression restoration in key disease regions.

White Cliff Minerals has revealed promising airborne geophysical data identifying multiple new high-priority copper targets adjacent to the Danvers deposit in Nunavut, signaling significant exploration upside at the Rae Copper Project.

PMET Resources has successfully produced commercial-grade pollucite concentrate from its Shaakichiuwaanaan Project, revealing a promising pathway to valuable caesium co-products alongside lithium and tantalum.

Terra Critical Minerals (ASX – T92) has revealed extensive high-grade silver mineralisation across its 100% owned Mole River project in NSW, highlighting significant polymetallic potential and setting the stage for a major exploration push.

Neurotech International has secured a key FDA designation for its lead drug NTI164, advancing its potential to treat Rett syndrome with regulatory and financial benefits.

Corazon Mining has secured an exclusive 12-month option to acquire an 80% stake in the Feather Cap Gold Project, expanding its footprint in Western Australia's prolific Gascoyne region. The project boasts significant historical gold mineralisation and offers promising exploration upside near Corazon’s Two Pools Project.

Minerals 260 Limited’s latest drilling results at the Bullabulling Gold Project reveal thick, shallow high-grade gold intercepts that underpin a forthcoming resource upgrade. The company advances its Pre-Feasibility Study with confidence, eyeing a December 2025 Mineral Resource Estimate update.

Arovella Therapeutics has demonstrated that its novel CLDN18.2 CAR-T cells effectively eliminate pancreatic cancer cells in vitro, matching the performance of a leading competitor’s product. The company is now advancing this CAR into its innovative iNKT cell platform to tackle solid tumours.